KOD Dec 2024 5.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.3500

0.0000

(0.00%)

As of 01:28PM EDT. Market open.

Loading interactive chart…

Zacks
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Zacks
Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PR Newswire
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences: